1. Froimchuk, Eugene, Jang, Younghoon, Ge, Kai. 2017. Histone H3 lysine 4 methyltransferase KMT2D. In Gene, 627, 337-342. doi:10.1016/j.gene.2017.06.056. https://pubmed.ncbi.nlm.nih.gov/28669924/
2. Ma, Mengjie, Zhou, Jiafeng, Ma, Zhihua, Shu, Pengcheng, Peng, Xiaozhong. 2022. The Ash2l SDI Domain Is Required to Maintain the Stability and Binding of DPY30. In Cells, 11, . doi:10.3390/cells11091450. https://pubmed.ncbi.nlm.nih.gov/35563756/
3. Zhao, Yanfang, Hao, Xiaoxiao, Li, Zhaofei, Jiang, Hao, Zhang, Ping. 2022. Role of chromatin modulator Dpy30 in osteoclast differentiation and function. In Bone, 159, 116379. doi:10.1016/j.bone.2022.116379. https://pubmed.ncbi.nlm.nih.gov/35307321/
4. Liu, Bing. 2018. DPY30 functions in glucose homeostasis via integrating activated histone epigenetic modifications. In Biochemical and biophysical research communications, 507, 286-290. doi:10.1016/j.bbrc.2018.11.023. https://pubmed.ncbi.nlm.nih.gov/30448059/
5. Su, Wei-Chao, Mao, Xiao-Mei, Li, Si-Yang, Su, Guo-Qiang, Shen, Dong-Yan. 2023. DPY30 Promotes Proliferation and Cell Cycle Progression of Colorectal Cancer Cells via Mediating H3K4 Trimethylation. In International journal of medical sciences, 20, 901-917. doi:10.7150/ijms.80073. https://pubmed.ncbi.nlm.nih.gov/37324189/
6. Mei, Pei-Yuan, Xiao, Han, Guo, Qiang, Huang, Quan-Fu, Liao, Yong-De. 2022. Identification and validation of DPY30 as a prognostic biomarker and tumor immune microenvironment infiltration characterization in esophageal cancer. In Oncology letters, 25, 68. doi:10.3892/ol.2022.13654. https://pubmed.ncbi.nlm.nih.gov/36644145/
7. Shah, Kushani K, Whitaker, Robert H, Busby, Theodore, Placzek, William J, Jiang, Hao. 2019. Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth. In Experimental cell research, 382, 111485. doi:10.1016/j.yexcr.2019.06.030. https://pubmed.ncbi.nlm.nih.gov/31251903/
8. Dixit, Deobrat, Prager, Briana C, Gimple, Ryan C, Bao, Shideng, Rich, Jeremy N. 2022. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. In Science translational medicine, 14, eabf3917. doi:10.1126/scitranslmed.abf3917. https://pubmed.ncbi.nlm.nih.gov/34985972/
智鼠故事 
